Skip to main content Skip to megamenu (after main content)
Meet us next:   BIO International Convention 2025 – 4 September  ●  ELRIG – Drug Discovery in Scotland 2025 – 17 September  ●  The Cell & Gene Meeting on the Mesa 2025 – 6-8 October (in person) & 9-10 October (virtual)  ●  ELRIG – Drug Discovery – 21-22 October  ●  more on our events calendar
Prices for NutriStem, NutriCoat, and NutriFreez products will increase effective 1st August. Lock in the current price by getting your order by 31st July.

How is Stemchymal® performing in Clinical Trials? [Infographic]

By Zara Puckrin BSc, digital marketing manager, REPROCELL Europe
Mesenchymal stem cells Cells under fluorescent microscope

Stemchymal®[1] is an allogenic stem cell therapeutic derived from the adipose tissue of healthy donors. Mesenchymal stem cells (MSCs) are isolated from the adipose tissue using a propriety cell processing system developed by Steminent Biotherapeutics[2].  The purified MSCs are then administered to patients via Intravenous (IV) infusion.

Stemchymal cell therapy for SCA3

Currently, Stemchymal® is being trailed for the treatment of Spinocerebellar Ataxia 3 (SCA3) a condition characterized by progressive cerebellar ataxia. So far, the treatment has been deemed safe for IV administration. You can discover the main findings from the phase I and phase II trials in our infographic below.

Infographic Stemchymal Progress So far

Stemchymal phase I/II clinical trials 

In this infographic we have summarized the main findings from the Phase I/II clinical trials of Stemchymal®. We have also provided information on the disease this therapeutic aims to treat, and a timeline of how the drug is progressing clinically in different countries. Inquire now to find out more about our clinical capabilities → 

Scientist in stem cell clinical lab

Clinical Laboratory Services

We offer comprehensive customised laboratory services for clinical research.

Discover more

References

  1. What is Stemchymal® - Steminent Biotherapeutics
  2. About Steminent - Steminent Biotherapeutics 
  3. Tang et al. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch Neuro 57:4 (2000)
  4. Tsai et al. Treatment of Spinocerebellar Ataxia 3 with Mesenchymal Stem Cell treatment Stemchymal. Cell Trans 26 (2017)